Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer

This study is testing a new CAR-T cell therapy called IM96 for patients with advanced colorectal cancer that has not responded to standard treatments. CAR-T therapy uses your own immune cells, which are engineered in a lab to find and destroy cancer cells that carry a specific protein called GUCY2C. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced (metastatic) colorectal cancer confirmed by biopsy - You have already tried at least two standard treatments that either stopped working or caused intolerable side effects - Your cancer cells test positive for the GUCY2C protein - You have at least one measurable tumor visible on imaging - Your expected survival is at least 3 months - You are in reasonably good physical condition (ECOG 0-1) **You may NOT be eligible if...** - You have active infection (including HIV or hepatitis) - You have severe heart, liver, kidney, or lung problems - You are pregnant or unwilling to use contraception during and after the study - You have a history of severe autoimmune disease Talk to your doctor to see if this trial is right for you.